Claudio Gobbi

Lugano, TI, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 191 publications

Serum Glial Fibrillary Acidic Protein Dynamics, Disease Progression, and Therapy Response in Multiple Sclerosis.

Serum Glial Fibrillary Acidic Protein Dynamics, Disease Progression, and Therapy Response in Multiple Sclerosis.

Journal: JAMA neurology

Published: August 03, 2026

Emerging CSF and Serum Biomarkers in Multiple Sclerosis: Cytokines, MOG, GFAP, and Beyond.

Emerging CSF and Serum Biomarkers in Multiple Sclerosis: Cytokines, MOG, GFAP, and Beyond.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: April 23, 2026

Anti-CGRP monoclonal antibody therapy for migraine is not associated with early adverse bone effects: a prospective, observational, controlled, cohort study.

Anti-CGRP monoclonal antibody therapy for migraine is not associated with early adverse bone effects: a prospective, observational, controlled, cohort study.

Journal: Frontiers in neurology

Published: April 09, 2026

Keeping cool - how persons with MS manage heat sensitivity: Insights from the Swiss multiple sclerosis registry.

Keeping cool - how persons with MS manage heat sensitivity: Insights from the Swiss multiple sclerosis registry.

Journal: Multiple sclerosis and related disorders

Published: April 08, 2026

Whole anterior visual pathway segmentation from high-resolution MRI using artificial intelligence.

Whole anterior visual pathway segmentation from high-resolution MRI using artificial intelligence.

Journal: European radiology experimental

Published: January 19, 2026

Human Prion Disease: Pathogenesis, Diagnosis and Public Health.

Human Prion Disease: Pathogenesis, Diagnosis and Public Health.

Journal: Viruses

Published: December 16, 2025

Use of complementary therapies is associated with expectations of treatment effectiveness among persons with multiple sclerosis.

Use of complementary therapies is associated with expectations of treatment effectiveness among persons with multiple sclerosis.

Journal: BMJ neurology open

Published: December 04, 2025

Precision Neuromodulation Treatment Reverses Motor and Cognitive Slowing After Stroke: Clinical and Neurophysiological Evidence.

Precision Neuromodulation Treatment Reverses Motor and Cognitive Slowing After Stroke: Clinical and Neurophysiological Evidence.

Journal: Journal of clinical medicine

Published: December 01, 2025

Patient SAtisfaction with the TYSabri SC Formulation - A Swiss multi-centriC, prospective non-intervenTIONal study: the SATYSFACTION study.

Patient SAtisfaction with the TYSabri SC Formulation - A Swiss multi-centriC, prospective non-intervenTIONal study: the SATYSFACTION study.

Journal: Therapeutic advances in neurological disorders

Published: November 25, 2025

Clinical and Genetic Factors Associated with Non-Response to Erenumab.

Clinical and Genetic Factors Associated with Non-Response to Erenumab.

Journal: Journal of clinical medicine

Published: November 14, 2025

Serum GFAP as a biomarker for progression in multiple sclerosis: assay comparison and a large reference database of healthy controls.

Serum GFAP as a biomarker for progression in multiple sclerosis: assay comparison and a large reference database of healthy controls.

Journal: Clinical chemistry and laboratory medicine

Published: November 08, 2025

Biomarker discovery using NUcleic Acid-Linked Immuno-Sandwich Assay in multiple sclerosis patients experiencing progression independent of relapse activity.

Biomarker discovery using NUcleic Acid-Linked Immuno-Sandwich Assay in multiple sclerosis patients experiencing progression independent of relapse activity.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: November 05, 2025

Showing 1-12 of 191

Last Updated: 09/26/2026